MedAvante-ProPhase, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MedAvante-ProPhase, Inc - overview
Established
2002
Location
Hamilton, NY, US
Primary Industry
Pharmaceuticals
About
MedAvante-ProPhase, Inc is a clinical trial support company focused on enhancing participant safety and improving research efficiency through advanced data intelligence and comprehensive service offerings. Founded in 2002 in Hamilton, US, MedAvante-ProPhase, Inc specializes in clinical trial management solutions. The company has participated in 4 deals, with the latest funding round occurring in May 2017, raising USD 20. 00 mn from Goldman Sachs Merchant Banking Division and Trevi Health Ventures.
Paul Gilbert serves as both the founder and CEO, contributing his experience in the clinical research industry to lead the firm. MedAvante-ProPhase provides clinical trial support solutions that include Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) reviews, endpoint adjudication committees, and data safety monitoring. Their services aim to enhance participant safety and minimize risks associated with clinical research. The company supports a wide range of clients, including pharmaceutical and biotechnology companies, research sites, and contract research organizations (CROs) globally, focusing on recruitment, retention, clinical trial training, and financial management to ensure compliance and resource optimization.
In 2016, MedAvante-ProPhase reported revenue of USD 60. 00 mn, primarily generated through service contracts with research sponsors and CROs. Revenue streams include flat-rate fees for services like IRB reviews and subscription access to their proprietary tools. Their flagship products, such as ClinSphere™ and AIMS®, contribute to their revenue by providing innovative trial management solutions.
MedAvante-ProPhase plans to leverage its recent funding of USD 20. 00 mn from the May 2017 round to support the development of new products aimed at enhancing trial management capabilities. The company is also looking to expand its services into additional geographic regions, specifically targeting markets in Europe and Asia by the end of 2018. This strategy is part of their growth initiative following the acquisition by WIRB-Copernicus Group, which provides an opportunity for increased integration and resource sharing.
Current Investors
WIRB Copernicus Group, Inc.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.medavante.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
MedAvante-ProPhase, Inc - financials
| Fiscal Year Ended | Dec 31, 2016 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
MedAvante-ProPhase, Inc - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | MedAvante-ProPhase, Inc | - | ||||||||
| Add-on | Completed | MedAvante-ProPhase, Inc | - | ||||||||
| Secondary Buyout | Completed | MedAvante-ProPhase, Inc | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.